- Home
- WEA vs FATE Comparison
WEA vs FATE Comparison
Compare WEA & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- FATE
- Stock Information
- Founded
- WEA 2002
- FATE 2007
- Country
- WEA United States
- FATE United States
- Employees
- WEA N/A
- FATE N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEA Finance
- FATE Health Care
- Exchange
- WEA Nasdaq
- FATE Nasdaq
- Market Cap
- WEA 131.1M
- FATE 142.4M
- IPO Year
- WEA N/A
- FATE 2013
- Fundamental
- Price
- WEA $10.89
- FATE $1.42
- Analyst Decision
- WEA
- FATE Hold
- Analyst Count
- WEA 0
- FATE 10
- Target Price
- WEA N/A
- FATE $6.75
- AVG Volume (30 Days)
- WEA 46.1K
- FATE 2.0M
- Earning Date
- WEA 01-01-0001
- FATE 03-04-2025
- Dividend Yield
- WEA 7.87%
- FATE N/A
- EPS Growth
- WEA N/A
- FATE N/A
- EPS
- WEA N/A
- FATE N/A
- Revenue
- WEA N/A
- FATE $13,447,000.00
- Revenue This Year
- WEA N/A
- FATE N/A
- Revenue Next Year
- WEA N/A
- FATE N/A
- P/E Ratio
- WEA N/A
- FATE N/A
- Revenue Growth
- WEA N/A
- FATE N/A
- 52 Week Low
- WEA $9.60
- FATE $1.04
- 52 Week High
- WEA $11.29
- FATE $8.83
- Technical
- Relative Strength Index (RSI)
- WEA 46.16
- FATE 48.76
- Support Level
- WEA $10.90
- FATE $1.43
- Resistance Level
- WEA $11.05
- FATE $1.81
- Average True Range (ATR)
- WEA 0.13
- FATE 0.14
- MACD
- WEA -0.01
- FATE 0.05
- Stochastic Oscillator
- WEA 28.00
- FATE 39.06
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.